These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11433889)

  • 1. [Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
    Gonçalves JV; Caldeira J
    Rev Port Cardiol; 2001 Apr; 20(4):439-45. PubMed ID: 11433889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of myocardial protection in type 2 diabetic patients.
    Lee TM; Chou TF
    J Clin Endocrinol Metab; 2003 Feb; 88(2):531-7. PubMed ID: 12574175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
    Nieszner E; Posa I; Kocsis E; Pogátsa G; Préda I; Koltai MZ
    Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry.
    Danchin N; Charpentier G; Ledru F; Vaur L; Guéret P; Hanania G; Blanchard D; Lablanche JM; Genès N; Cambou JP
    Diabetes Metab Res Rev; 2005; 21(2):143-9. PubMed ID: 15386810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.
    Schotborgh CE; Wilde AA
    Cardiovasc Res; 1997 Apr; 34(1):73-80. PubMed ID: 9217875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfonylurea drugs and insulin-independent diabetes mellitus.
    Lebovitz HE; Feinglos MN
    Compr Ther; 1979 Apr; 5(4):65-71. PubMed ID: 445991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
    Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sulfonylurea controversy: more questions from the heart.
    Brady PA; Terzic A
    J Am Coll Cardiol; 1998 Apr; 31(5):950-6. PubMed ID: 9561992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antidiabetic drugs: preoperative stop or continue?
    Poortmans G
    Acta Anaesthesiol Belg; 2001; 52(4):403-7. PubMed ID: 11799573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
    Monami M; Genovese S; Mannucci E
    Diabetes Obes Metab; 2013 Oct; 15(10):938-53. PubMed ID: 23594109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral sulfonylureas and CV mortality.
    Aronow WS
    Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
    [No Abstract]   [Full Text] [Related]  

  • 15. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction.
    Halkin A; Roth A; Jonas M; Behar S
    J Thromb Thrombolysis; 2001 Oct; 12(2):177-84. PubMed ID: 11729370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hypoglycemic sulphonylureas in arrhythmias contributing to the mortality in acute myocardial ischemia.
    Koltai MZ; Aranyi Z; Ballagi-Podány G; Pogátsa G
    Acta Physiol Hung; 1990; 75 Suppl():175-6. PubMed ID: 2371854
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
    Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
    CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes.
    Weih M; Amberger N; Wegener S; Dirnagl U; Reuter T; Einhäupl K
    Stroke; 2001 Sep; 32(9):2029-32. PubMed ID: 11546892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemic adverse reactions to insulin and sulfonylureas.
    O'Donnell J
    Leg Med; 1993; ():193-232. PubMed ID: 8121229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Mühlhauser I; Sawicki PT; Berger M
    Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.